Jerzak, K.J.; Sehdev, S.; Boileau, J.-F.; Brezden-Masley, C.; Califaretti, N.; Edwards, S.; Gordon, J.; Henning, J.-W.; LeVasseur, N.; Railton, C.
Multidisciplinary Practical Guidance for Implementing Adjuvant CDK4/6 Inhibitors for Patients with HR-Positive, HER2-Negative Early Breast Cancer in Canada. Curr. Oncol. 2025, 32, 444.
https://doi.org/10.3390/curroncol32080444
AMA Style
Jerzak KJ, Sehdev S, Boileau J-F, Brezden-Masley C, Califaretti N, Edwards S, Gordon J, Henning J-W, LeVasseur N, Railton C.
Multidisciplinary Practical Guidance for Implementing Adjuvant CDK4/6 Inhibitors for Patients with HR-Positive, HER2-Negative Early Breast Cancer in Canada. Current Oncology. 2025; 32(8):444.
https://doi.org/10.3390/curroncol32080444
Chicago/Turabian Style
Jerzak, Katarzyna J., Sandeep Sehdev, Jean-François Boileau, Christine Brezden-Masley, Nadia Califaretti, Scott Edwards, Jenn Gordon, Jan-Willem Henning, Nathalie LeVasseur, and Cindy Railton.
2025. "Multidisciplinary Practical Guidance for Implementing Adjuvant CDK4/6 Inhibitors for Patients with HR-Positive, HER2-Negative Early Breast Cancer in Canada" Current Oncology 32, no. 8: 444.
https://doi.org/10.3390/curroncol32080444
APA Style
Jerzak, K. J., Sehdev, S., Boileau, J.-F., Brezden-Masley, C., Califaretti, N., Edwards, S., Gordon, J., Henning, J.-W., LeVasseur, N., & Railton, C.
(2025). Multidisciplinary Practical Guidance for Implementing Adjuvant CDK4/6 Inhibitors for Patients with HR-Positive, HER2-Negative Early Breast Cancer in Canada. Current Oncology, 32(8), 444.
https://doi.org/10.3390/curroncol32080444
